Cure8 research brief
Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.
This study reports PK and immunogenicity similarity in healthy volunteers, a step toward potential biosimilar approval but not evidence of clinical effectiveness in IBD.
Patients on ustekinumab or considering biologic therapy, IBD clinicians, researchers, and regulators.
A randomized open-label comparative trial tested GNR-068, a proposed biosimilar to ustekinumab (Stelara®), versus the reference product after a single 45 mg subcutaneous dose in healthy male volunteers.
The study reported pharmacokinetic similarity (AUC0–∞ and Cmax within the 80–125% equivalence margin), similar adverse event rates, and a lower incidence of anti-drug antibodies (ADA) in the GNR-068 group.
These findings are from the article abstract reporting a controlled PK/immunogenicity study in healthy volunteers, not from patients with inflammatory bowel disease. The trial focuses on safety, PK, and immunogenicity after one dose; it does not provide efficacy data in Crohn’s disease or ulcerative colitis.
If GNR-068 proceeds through further trials and gains regulatory approval as a biosimilar, it could increase treatment options and potentially reduce costs for indications currently treated with ustekinumab, including Crohn’s disease and ulcerative colitis.
Findings are from a single-dose PK/immunogenicity study in healthy male volunteers (abstract-level data). This does not establish clinical efficacy or long-term safety in Crohn’s disease or ulcerative colitis; further trials and regulatory review are required.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
